Two CAR T-Cell Therapies Greenlighted in Europe
Two CAR T-Cell Therapies Greenlighted in Europe

Two CAR T-Cell Therapies Greenlighted in Europe

Cancer treatments from Novartis and Gilead earn approval from EU regulators, but a first pass by the UK’s state-funded health service finds CAR T is too expensive. 

Jef Akst
Jef Akst

Jef Akst is managing editor of The Scientist, where she started as an intern in 2009 after receiving a master’s degree from Indiana University in April 2009 studying the mating behavior of seahorses.

View full profile.

Learn about our editorial policies.

Aug 28, 2018


Update (September 19): Although the National Institute for Health and Care Excellence (NICE) decided that Kymriah could be used in young patients with hard-to-treat leukemia, the agency ruled that the therapy is not cost-effective for adults with lymphoma.

Update (September 5): Novartis struck a deal with the UK’s National Health Service to accelerate the delivery of Kymriah to young leukemia patients not responding to other treatments, Reuters reports. List price in the country is £282,000 ($361,750) per patient.

The European Commission has approved the use of Novartis’s tisagenlecleucel (Kymriah) and Gilead’s axicabtagene ciloleucel (Yescarta), two chimeric antigen receptor T cell (CAR T) therapies, for certain cancer patients. This new class of therapies has been hailed as a breakthrough in cancer treatment, but cost is a sticking point.

Just one day after the European Commission greenlighted Yescarta, the National Institute for Health and Care Excellence (NICE)...

“If we’re going to see CAR-T therapy widely available on the NHS, we need to find ways to reduce the costs,” Raj Chopra, head of cancer therapeutics at the Institute of Cancer Research in London, tells Reuters

See “Cell and Gene Therapy Tracker: Global CAR T-Cell Trials

NICE is still evaluating Kymriah. Final decisions on whether the NHS will cover the immunotherapies are expected later this year, according to PharmaTimes.

Following the European Commission’s approval, Kymriah, which received approval from the US Food and Drug Administration (FDA) a year ago, will be available to patients in Europe who are 25 years old or younger and have relapsed or refractory B-cell acute lymphoblastic leukemia (ALL) and to adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Yescarta, approved in the US last October, has been cleared for challenging cases of DLBCL as well as treatment-resistant primary mediastinal large B-cell lymphoma.

See “Making CAR T-Cell Therapy Safer

Interested in reading more?

The Scientist ARCHIVES

Become a Member of

Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member?